Ready Tevagrastim drug solution should be stored at primobolan results is not more than a day.
Standard regimens of cytotoxic chemotherapy
in a dose of 5 mg (0.5 million. IU) / kg once a day every day n / or / as a short infusion (30 min), 5% dextrose solution. The first dose administered no earlier than 24 hours after the completion of cytotoxic chemotherapy. If necessary, the course treatment duration may be up to 14 days, depending on the severity of the disease and severity of neutropenia. Following induction and consolidation therapy of acute myeloid leukemia the duration of the use Tevagrastim drug may increase up to 38 days depending on the type, dose and use the scheme of cytotoxic chemotherapy.
A transient increase in neutrophil counts is typically seen after 1-2 days after the start of treatment with Tevagrastim. To achieve a stable therapeutic effect should continue therapy with Tevagrastim as long as the number of neutrophils can not pass the expected minimum and will not reach normal values.
It is not recommended to cancel the drug primobolan results prematurely, before the transfer of the neutrophil count over the expected minimum.
Following myeloablative chemotherapy followed by a bone marrow transplantation
n / or / as an infusion in 20 ml of 5% dextrose solution. The first dose of drug to be administered Tevagrastim not earlier than 24 hours after cytotoxic chemotherapy and in bone marrow transplantation – not later than 24 hours after bone marrow infusion. Duration of therapy is no more than 28 days. After reducing the maximum number of neutrophils (nadir), the daily dose is adjusted depending on the number of speakers. If the number of neutrophils in the peripheral blood of more than for three consecutive days, the dose reduced to primobolan results; then, if the exceeds for three consecutive days, the drug overturned.If the treatment period is reduced below , the dose of the drug Tevagrastim increase again in accordance with the above scheme.
Mobilization of peripheral blood stem cells after myelosuppressive therapy with autologous transfusion with (or without) or bone marrow transplantation in patients with myeloablative therapy with subsequent transfusion
At a dose of 10 mg (1.0 million. IU) / kg by n / injection to 1 times per day or continuous 24chasovoy p / infusion for 6 consecutive days, with usually only two leukapheresis procedure in a row on the 5th, 6th days. In some cases, the possibility of further leukapheresis. Use of the drug Tevagrastim should continue until the last leukapheresis.
PBSC mobilization after myelosuppressive therapy
in a dose of 5 mg (0.5 million. IU) / kg daily by n / k injections starting on the first day after completion of chemotherapy and as long as the number of neutrophils can not pass through the expected minimum and reaches normal values. Leukapheresis be carried out during the period when the primobolan results is raised to less than 0.5 x 10 9 / L to more than 5.0 x 10 9 / L. Patients not receiving intensive chemotherapy, one leukapheresis is enough. In some cases, it is recommended to conduct additional leukapheresis.
PBSC mobilization in healthy doporov for allogeneic transplantation
in a dose of 10 micrograms (1.0 mln. IU) / kg / day p / c, for 4-5 days. Leukapheresis is carried out with the 5th day, and if necessary to 6th days to obtain in an amount of not less than 4 x 10 6cells / kg body weight of the recipient. The efficacy and safety of the drug in healthy donors Tevagrastim younger than 16 and older than 60 years have not been studied.